Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis
Annals of Pharmacotherapy · 20.11.2026
DOI: 10.1177/10600280261500503 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 20.11.2026. Verfasst von Christos-Nikiforos Balapanidis-Parisis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Die Arbeit nennt 100 Literaturangaben.
Abstract (Originalsprache)
Objective
Amitriptyline remains in use among older adults despite safety concerns. This diagnosis-independent systematic review and meta-analysis evaluated amitriptyline safety and tolerability versus active comparators or placebo in older adults. Data Sources: We searched MEDLINE, CENTRAL, Embase, PsycINFO, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) through September 30, 2026. Study Selection and Data Extraction: Eligible randomized controlled trials (RCTs) compared amitriptyline with placebo or active comparators in older adults (participants aged ≥60 years or study populations with mean age ≥70 years). Primary outcomes included serious adverse events (SAEs), dizziness, and acute cognitive adverse outcomes. Secondary outcomes included 60 safety, tolerability, and acceptability outcomes. Risk ratios (RRs) and mean differences were calculated. Random-effects meta-analyses were conducted separately versus placebo and active comparators on an intention-to-treat basis. Subgroup and sensitivity analyses explored robustness. Data Synthesis: In total, 32 RCTs (2243 participants) were included. Versus active comparators, that is, antidepressants or mood stabilizers, amitriptyline did not increase serious adverse events (SAEs) (RR = 1.13; 95% CI, 0.66-1.93), but increased dizziness (RR = 1.38; 95% CI, 1.06-1.79). Regarding cognition, no difference was found for disturbance in attention (RR = 2.44; 95% CI, 0.89-6.71) or confusional state (RR = 1.76; 95% CI, 0.42-7.35); disorientation was reported in 1 trial. Amitriptyline was associated with increased risk of any adverse event, withdrawals due to adverse events, anticholinergic and sedative adverse events, and weight gain. Placebo-controlled data were sparse, with no SAEs reported. Limitations included short trials, sparse adverse event reporting, and restricted eligibility. Relevance to Patient Care and Clinical Practice: Amitriptyline’s main limitation in older adults may be tolerability rather than excess serious harm. It should not be a first-line option, but may remain reasonable for selected patients with clear therapeutic rationale.
Conclusion
Compared with active comparators, amitriptyline showed no detectable excess in SAEs but increased dizziness and anticholinergic and sedative adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
- Department of Psychiatry, School of Medicine, University of Thessaly, Larissa, Greece.
- Department of Geriatric Psychiatry, Aneurin Bevan University Health Board, Newport, UK.
ORCID-Profile: Christos-Nikiforos Balapanidis-Parisis, Anastasios Stefanou, Evangelos Ntouros, Andreas S Lappas, Vasilios-Panteleimon Bozikas
Zitieren
APA
Balapanidis-Parisis, C. N., Stefanou, A., Ntouros, E., Lappas, A. S., Bozikas, V. P., & Samara, M. T. (2026). Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261500503
Vancouver
Balapanidis-Parisis CN, Stefanou A, Ntouros E, Lappas AS, Bozikas VP, Samara MT. Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261500503
BibTeX
@article{BalapanidisParisis2026,
author = {Balapanidis-Parisis, Christos-Nikiforos and Stefanou, Anastasios and Ntouros, Evangelos and Lappas, Andreas S and Bozikas, Vasilios-Panteleimon and Samara, Myrto T},
title = {Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261500503}
}
EUVIMED